Heart failure / hypoxia

Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure

Solo gli utenti registrati possono tradurre articoli

Entra registrati

FIELD OF THE INVENTION The present invention relates to methods of identifying whether a candidate compound is a modulator of an orphan G protein-coupled receptor (GPCR). Preferably the GPCR is human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the

Methods for increasing the stabilization of hypoxia inducible factor-.alpha.

Solo gli utenti registrati possono tradurre articoli

Entra registrati

FIELD OF THE DISCLOSURE Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed

Methods for increasing the stabilization of hypoxia inducible factor-1 alpha

Solo gli utenti registrati possono tradurre articoli

Entra registrati

FIELD OF THE DISCLOSURE Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed

Methods for increasing the stabilization of hypoxia inducible factor-1 alpha

Solo gli utenti registrati possono tradurre articoli

Entra registrati

FIELD OF THE DISCLOSURE Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed

Methods for increasing the stabilization of hypoxia inducible factor-1 alpha

Solo gli utenti registrati possono tradurre articoli

Entra registrati

FIELD OF THE DISCLOSURE Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed

Prodrug salts

Solo gli utenti registrati possono tradurre articoli

Entra registrati

TECHNICAL FIELD Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their

Prodrug salts

Solo gli utenti registrati possono tradurre articoli

Entra registrati

TECHNICAL FIELD Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their

Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors

Solo gli utenti registrati possono tradurre articoli

Entra registrati

FIELD OF THE INVENTION This invention describes the use of rho GTPase function inhibitors as upregulators of Type III endothelial cell Nitric Oxide Synthase. Further, this invention describes methods that employ Rho GTPase function inhibitors to treat conditions that result from the abnormally low

Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization

Solo gli utenti registrati possono tradurre articoli

Entra registrati

FIELD OF THE INVENTION This invention relates to the use of agents that disrupt actin cytoskeletal organization as upregulators of Type III endothelial cell Nitric Oxide Synthase. Further, this invention relates to methods that employ agents that disrupt actin cytoskeletal organization to treat

Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders

Solo gli utenti registrati possono tradurre articoli

Entra registrati

TECHNICAL FIELD This invention relates to the treatment of respiratory, cardiac and blood disorders by delivery into the lungs of compound comprising NO. BACKGROUND OF THE INVENTION Inhaled NO is used to treat elevated pulmonary pressures and pulmonary disorders associated with hypoxemia. This

Method of treating cardio pulmonary diseases with no group compounds

Solo gli utenti registrati possono tradurre articoli

Entra registrati

TECHNICAL FIELD This invention relates to the treatment of respiratory, cardiac and blood disorders by delivery into the lungs of compound comprising NO substitute. BACKGROUND OF THE INVENTION Inhaled NO is used to treat elevated pulmonary pressures and pulmonary disorders associated with hypoxemia.

Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors

Solo gli utenti registrati possono tradurre articoli

Entra registrati

FIELD OF THE INVENTION This invention describes the new use of HMG-CoA reductase inhibitors as upregulators of Type III endothelial cell Nitric Oxide Synthase. Further, this invention describes methods that employ HMG-CoA reductase inhibitors to treat conditions that result from the abnormally low

Methods for early detection of heart disease

Solo gli utenti registrati possono tradurre articoli

Entra registrati

FIELD OF THE INVENTION This invention relates generally to the area of diagnosis of heart disease, and specifically relates to methods of diagnosis of heart failure, cardiac ischemia, or hypoxia by detecting the level, e.g., concentration, of a non-polypeptidic cardiac marker as an indicator of

Kits for early detection of heart disease

Solo gli utenti registrati possono tradurre articoli

Entra registrati

FIELD OF THE INVENTION This invention relates generally to the area of diagnosis of heart disease, and specifically relates to methods of diagnosis of heart failure, cardiac ischemia, or hypoxia by detecting the level, e.g., concentration, of a non-polypeptidic cardiac marker as an indicator of

Compositions and methods for early detection of heart disease

Solo gli utenti registrati possono tradurre articoli

Entra registrati

FIELD OF THE INVENTION This invention relates generally to the area of diagnosis of heart disease, and specifically relates to methods of diagnosis of heart failure, cardiac ischemia, or hypoxia by detecting the level, e.g., concentration, of a non-polypeptidic cardiac marker as an indicator of

heart failure/hypoxia

Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure

Methods for increasing the stabilization of hypoxia inducible factor-.alpha.

Methods for increasing the stabilization of hypoxia inducible factor-1 alpha

Methods for increasing the stabilization of hypoxia inducible factor-1 alpha

Methods for increasing the stabilization of hypoxia inducible factor-1 alpha

Prodrug salts

Prodrug salts

Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors

Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization

Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders

Method of treating cardio pulmonary diseases with no group compounds

Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors

Methods for early detection of heart disease

Kits for early detection of heart disease

Compositions and methods for early detection of heart disease

Il database di erbe medicinali più completo supportato dalla scienza